Novo Nordisk’s Ultra Fast-Acting Insulin On Course To Indian Debut

 
• By Anju Ghangurde

Novo Nordisk is gearing towards the potential launch of its ultra fast-acting insulin aspart, Fiasp, in India. Pricing and how the product will be positioned alongside NovoRapid (conventional insulin aspart) are expected to be closely watched by competition.

Indian currency
NOVO NORDISK IS GEARING TO INTRODUCE FIASP IN INDIA

More from Business

More from Scrip